| Article Access Statistics|
| Viewed||4404 |
| Printed||81 |
| Emailed||0 |
| PDF Downloaded||19 |
| Comments ||[Add] |
| Cited by others ||3 |
Click on image for details.
|Year : 2021 | Volume
| Issue : 3 | Page : 180-181
Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
B Roca1, M Rambla1, M Manuel Roca2
1 Department of Medicine, Hospital General de Castellon, Castellon, Spain
2 Department of Ophthalmology, Hospital of Vinaros, Castellon, Spain
|Date of Submission||17-Mar-2021|
|Date of Decision||24-Mar-2021|
|Date of Acceptance||02-Jun-2021|
|Date of Web Publication||13-Aug-2021|
M Manuel Roca
Department of Ophthalmology, Hospital of Vinaros, Castellon
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Roca B, Rambla M, Roca M M. Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine. J Postgrad Med 2021;67:180-1
As COVID-19 vaccines are being authorized and recommended for use worldwide, it is important to understand what is known about them, particularly in terms of effectiveness and safety. Common side-effects from these vaccines include mild grade fever, fatigue, headache, myalgia, and pain at the injection site, but information available about them is still limited. Herein we report a patient who presented with supraclavicular reactive lymphadenopathies after receiving the COVID-19 BNT162b2 vaccine (Pfizer-BioNTech).
A previously healthy 29-year-old woman presented with a two-day history of mild discomfort and a lump in her left supraclavicular region. Seven days earlier she had received the first dose of above mentioned COVID-19 vaccine in ipsilateral deltoid muscle. On examination she was in good health. Two lymphadenopathies, 1.5 cm and 1 cm in diameter respectively, were noted in her left supraclavicular region [Figure 1]. Mild pain on pressure was also present in the vaccine injection site.
Her routine investigations, including blood cell counts, biochemistry and serologies, was normal. Chest radiograph was normal. Ultrasound examination disclosed two left supraclavicular lymphadenopathies [Figure 2] with no other abnormalities found in the neck or axillary regions. As the patient was otherwise asymptomatic, she uneventfully received the second dose of the same COVID-19 vaccine, 21 days after the first dose. She required no specific treatment. The lymphadenopathies progressively diminished in size and finally disappeared over the next few weeks.
Lymphatic vessels from the deltoid region drain in the axillary and supraclavicular lymph nodes, and both axillary and supraclavicular lymphadenopathies have been previously described as side effect of different vaccines., Recently two other cases of reactive lymphadenopathies following COVID-19 vaccinations, presenting as a lump in the neck, have been reported. But this a barely known side effect of COVID-19 vaccines. Since a diagnosis of malignancy is considered in patients presenting with left supraclavicular lymphadenopathies, awareness of this side effect of COVID-19 vaccines is particularly important to avoid unnecessary evaluation and reduce anxiety of affected patients.
Declaration of patient consent
The authors certify that appropriate patient consent was obtained.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| :: References|| |
Wu CP, Adhi F, Culver D. Vaccination for COVID-19: Is it important and what should you know about it? Clevel Clin J Med 2021 (in press).
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al
. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16.
Pereira MP, Flores P, Neto AS. Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination. BMJ Case Rep 2019;12:e231582.
Toy H, Karasoy D, Keser M. Lymphadenitis caused by H1N1 vaccination: Case report. Vaccine 2010;28:2158-60.
Mitchell OR, Dave R, Bekker J, Brennan PA. Supraclavicular lymphadenopathy following COVID-19 vaccination: An increasing presentation to the two-week wait neck lump clinic? Br J Oral Maxillofac Surg 2021;59:384-5.
Lehman CD, D'Alessandro HA, Mendoza DP, Succi MD, Kambadakone A, Lamb LR. Unilateral lymphadenopathy after COVID-19 vaccination: A practical management plan for radiologists across specialties. J Am Coll Radiol 2021;18:843-52.
[Figure 1], [Figure 2]
|This article has been cited by|
||Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination
| ||Tzu-Chuan Ho, Daniel Hueng-Yuan Shen, Chin-Chuan Chang, Hung-Pin Chan, Kuo-Pin Chuang, Cheng-Hui Yuan, Ciao-Ning Chen, Ming-Hui Yang, Yu-Chang Tyan |
| ||Vaccines. 2023; 11(3): 696 |
|[Pubmed] | [DOI]|
||Coincidence of sarcoidosis and a COVID-19 vaccine-associated hypermetabolic lymphadenopathy in a patient with a history of invasive breast cancer: A case report
| ||Asuka Kawabata, Toru Nakamura, Hanae Suzuki, Masayuki Yoshida, Yoshiro Otsuki, Natsuko Mori |
| ||International Journal of Surgery Case Reports. 2022; : 107098 |
|[Pubmed] | [DOI]|
||COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature
| ||Jihe Lim, Seun Ah Lee, Eun Kyung Khil, Sun-Ju Byeon, Hee Joon Kang, Jung-Ah Choi |
| ||Seminars in Oncology. 2021; |
|[Pubmed] | [DOI]|